Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (9)	4/8/2000 1:16:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 368

Mike, the comparison to antisense is IMO right on target. For therapeutic applications one has to worry about delivery issues; doesn't Sangamo have some sort of collaboration with a "protein delivery" specialist? From the S-1: <boiler plate> Also, delivery of ZFP transcription factors into cells in these and other environments is limited by a number of technical challenges, which we may be unable to surmount. <TGEN connection> In order to regulate a gene, the ZFP transcription factor must be delivered to a cell. We have licensed gene transfer technology from Targeted Genetics, Inc. for use with our Universal GeneTools in pharmaceutical discovery. We are evaluating this and other technologies for the delivery of ZFPs into cells. <SAB member> George N. ("Joe") Cox, Ph.D. is President and Chief Scientific Officer of Bolder Biotech, a protein delivery biotechnology company. Dr. Cox was Vice President, Research and Development at Sangamo from March 1995 to June 1998. He spent the previous 12 years of his career at Synergen, Inc., in various positions including Group Leader, Discovery Research, Chairman of Synergen's science counsel, Director of Animal Health Care, and Senior Scientist. Some links: Scroll to second paragraph of this summary of Carlos Barbas research" cancerresearch.org Links to some abstracts (for the PNAS articles one can click on to the full article) from Barbas (Barbas CF) group: "Design of polydactyl zinc-finger proteins for unique addressing within complex genomes" ncbi.nlm.nih.gov "Building zinc fingers by selection: toward a therapeutic application" ncbi.nlm.nih.gov And from "Pabo CO" "Dimerization of zinc fingers mediated by peptides evolved in vitro from random sequences" ncbi.nlm.nih.gov "Analysis of zinc fingers optimized via phage display: evaluating the utility of a recognition code" ncbi.nlm.nih.gov Try also "Berg JM," for example: "Zinc fingers in Caenorhabditis elegans: finding families and probing pathways" ncbi.nlm.nih.gov All three gentlemen are in the SGMO SAB, as you surely know by now having digested that S-1. And last, but not least: ncbi.nlm.nih.gov PB

To: Mike McFarland who wrote (9)	4/8/2000 10:49:00 PM
From: scaram(o)uche	Respond to of 368

optimized? evolved? engineered?

To: Mike McFarland who wrote (9)	4/9/2000 6:28:00 AM
From: scott_jiminez	Read Replies (1) \| Respond to of 368

Mike - some more ZFP background info and perhaps a general approach towards accessing essential basic science in the future. A while back I posted this on the Ariad thread: Message 12761380 I searched for 'Zinc finger' on PubMed and randomly selected this abstract as an example ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10753724&dopt=Books Just click on the zinc finger link for some background from Alberts et al. Specifically, 1. Introduction to the control of gene expression ncbi.nlm.nih.gov:80/books/mboc/mboc.cgi?code=090201782446183 and the ninth item down in the outline, 2. There Are Several Types of DNA-binding Zinc Finger Motifs ncbi.nlm.nih.gov:80/books/mboc/mboc.cgi?code=09020921547924 Reading this entire chapter should give you a reasonable jump start towards understanding Sangamo's science.